Crosser cleared for CTOs
This article was originally published in The Gray Sheet
Executive Summary
FlowCardia will launch its Crosser 14 high frequency ultrasound crossing catheter in the United States within the quarter, according to Director of Marketing Mark Page. The firm announced 510(k) clearance for the device, which uses a vibrating tip to facilitate guidewire passage through coronary chronic total occlusions, on Jan. 23. FlowCardia also announced Jan. 25 that three Crosser devices for peripheral CTOs were approved in Europe. Firms have struggled to enter the coronary CTO market with specialty devices (1"The Gray Sheet" March 6, 2006, p. 13)...
You may also be interested in...
Firms Face Uphill Battle To Break Open Chronic Total Occlusion Market
Despite recent advances in specialized guidewires, industry has struggled to develop effective new technologies to aid in opening coronary chronic total occlusions, according to interventionalists
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.